loxo-435
eli lilly
['loxo-435', 'solid tumor']
#aacr23 | section 46 | tuesday
ct119 - a first-in-human phase 1 study of loxo-435, a potent, highly isoform-selective fgfr3 inhibitor in advanced solid tumors with fgfr3 alterations (trial in progress)
xin gao, md 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.